GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tempest Therapeutics Inc (NAS:TPST) » Definitions » PB Ratio

Tempest Therapeutics (Tempest Therapeutics) PB Ratio : 2.86 (As of May. 08, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Tempest Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-08), Tempest Therapeutics's share price is $3.47. Tempest Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $1.21. Hence, Tempest Therapeutics's PB Ratio of today is 2.86.

The historical rank and industry rank for Tempest Therapeutics's PB Ratio or its related term are showing as below:

TPST' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 24.43
Current: 2.98

During the past 4 years, Tempest Therapeutics's highest PB Ratio was 24.43. The lowest was 0.00. And the median was 0.00.

TPST's PB Ratio is ranked worse than
58.47% of 1310 companies
in the Biotechnology industry
Industry Median: 2.5 vs TPST: 2.98

During the past 12 months, Tempest Therapeutics's average Book Value Per Share Growth Rate was -29.50% per year.

Back to Basics: PB Ratio


Tempest Therapeutics PB Ratio Historical Data

The historical data trend for Tempest Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tempest Therapeutics PB Ratio Chart

Tempest Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
PB Ratio
- 1.01 0.67 3.62

Tempest Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.67 2.24 3.19 - 3.62

Competitive Comparison of Tempest Therapeutics's PB Ratio

For the Biotechnology subindustry, Tempest Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tempest Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tempest Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Tempest Therapeutics's PB Ratio falls into.



Tempest Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Tempest Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=3.47/1.214
=2.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Tempest Therapeutics  (NAS:TPST) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Tempest Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Tempest Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Tempest Therapeutics (Tempest Therapeutics) Business Description

Traded in Other Exchanges
Address
2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005
Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.
Executives
Justin Trojanowski officer: Corporate Controller C/O TEMPEST THERAPEUTICS, INC., 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 94080
Nicholas Maestas officer: VP of Strategy and Finance 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 20005
Versant Venture Capital Vi, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Side Fund Iv, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Venture Capital Iv, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Iv, Llc 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Thomas Woiwode director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Vi Gp-gp, Llc 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Vi Gp, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Vantage Ii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp-gp, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Thomas W. Dubensky director, officer: President C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Samuel Whiting officer: Chief Medical Officer C/O TEMPEST THERAPEUTICS, INC., 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 94080
Rock Springs Capital Llc 10 percent owner 650 SOUTH EXETER STREET, SUITE 1070, BALTIMORE MD 21202